Plasma extracellular vesicle messenger RNA profiling identifies prognostic EV signature for non-invasive risk stratification for survival prediction of patients with pancreatic ductal adenocarcinoma
The prognosis of pancreatic ductal adenocarcinoma (PDAC) is one of the most dismal of all cancers and the median survival of PDAC patients is only 6 –8 months after diagnosis. While decades of research effort h... (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - February 3, 2023 Category: Hematology Authors: Yi Han, Pascal Drobisch, Alexander Kr üger, Doreen William, Konrad Grützmann, Lukas Böthig, Heike Polster, Lena Seifert, Adrian M. Seifert, Marius Distler, Mathieu Pecqueux, Carina Riediger, Verena Plodeck, Heiner Nebelung, Georg F. Weber, Christian Pi Tags: Research Source Type: research
Protein degradation: expanding the toolbox to restrain cancer drug resistance
Despite significant progress in clinical management, drug resistance remains a major obstacle. Recent research based on protein degradation to restrain drug resistance has attracted wide attention, and several... (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - January 24, 2023 Category: Hematology Authors: Hui Ming, Bowen Li, Jingwen Jiang, Siyuan Qin, Edouard C. Nice, Weifeng He, Tingyuan Lang and Canhua Huang Tags: Review Source Type: research
Novel CD19-specific γ/δ TCR-T cells in relapsed or refractory diffuse large B-cell lymphoma
T cell receptor (TCR)-T cells possess similar effector function, but milder and more durable signal activation compared with chimeric antigen receptor-T cells. TCR-T cell therapy is another active field of cel... (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - January 21, 2023 Category: Hematology Authors: Chenggong Li, Fen Zhou, Jing Wang, Qi Chang, Mengyi Du, Wenjing Luo, Yinqiang Zhang, Jia Xu, Lu Tang, Huiwen Jiang, Lin Liu, Haiming Kou, Cong Lu, Danying Liao, Jianghua Wu, Qiuzhe Wei & hellip; Tags: Research Source Type: research
How we treat primary immune thrombocytopenia in adults
Primary immune thrombocytopenia (ITP) is an immune-mediated bleeding disorder characterized by decreased platelet counts and an increased risk of bleeding. Multiple humoral and cellular immune abnormalities re... (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - January 19, 2023 Category: Hematology Authors: Xin-guang Liu, Yu Hou and Ming Hou Tags: Review Source Type: research
A pH-dependent anti-CD47 antibody that selectively targets solid tumors and improves therapeutic efficacy and safety
The antiphagocytic molecule CD47 is overexpressed in a wide variety of cancer cells, and antibodies targeting CD47 for cancer therapies are currently under intensive investigation. However, owing to the ubiqui... (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - January 17, 2023 Category: Hematology Authors: Yulu Li, Juan Liu, Wei Chen, Wei Wang, Fang Yang, Ximing Liu, Yao Sheng, Kaixin Du, Miaomiao He, Xueyuan Lyu, Huiyu Li, Linlin Zhao, Zhizhong Wei, Fengchao Wang, Sanduo Zheng and Jianhua Sui Tags: Research Source Type: research
Payload diversification: a key step in the development of antibody –drug conjugates
Antibody –drug conjugates (ADCs) is a fast moving class of targeted biotherapeutics that currently combines the selectivity of monoclonal antibodies with the potency of a payload consisting of cytotoxic agents.... (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - January 17, 2023 Category: Hematology Authors: Louise Conilh, Lenka Sadilkova, Warren Viricel and Charles Dumontet Tags: Review Source Type: research
The development of a cSMART-based integrated model for hepatocellular carcinoma diagnosis
Hepatocellular carcinoma (HCC) generally arises from a background of liver cirrhosis (LC). Patients with cirrhosis and suspected HCC are recommended to undergo serum biomarker tests and imaging diagnostic eval... (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - January 5, 2023 Category: Hematology Authors: Tong Wu, Rong Fan, Jian Bai, Zhao Yang, Yun-Song Qian, Lu-Tao Du, Chun-Ying Wang, Ying-Chao Wang, Guo-Qing Jiang, Dan Zheng, Xiao-Tang Fan, Bo Zheng, Jing-Feng Liu, Guo-Hong Deng, Feng Shen, He-Ping Hu & hellip; Tags: Correspondence Source Type: research
miRNome profiling of lung cancer metastases revealed a key role for miRNA-PD-L1 axis in the modulation of chemotherapy response
Locally advanced non-small cell lung cancer (NSCLC) is frequent at diagnosis and requires multimodal treatment approaches. Neoadjuvant chemotherapy (NACT) followed by surgery is the treatment of choice for ope... (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - December 31, 2022 Category: Hematology Authors: Roberto Cuttano, Tommaso Colangelo, Juliana Guarize, Elisa Dama, Maria Pia Cocomazzi, Francesco Mazzarelli, Valentina Melocchi, Orazio Palumbo, Elena Marino, Elena Belloni, Francesca Montani, Manuela Vecchi, Massimo Barberis, Paolo Graziano, Andrea Pasqui Tags: Research Source Type: research
FTL004, an anti-CD38 mAb with negligible RBC binding and enhanced pro-apoptotic activity, is a novel candidate for treatments of multiple myeloma and non-Hodgkin lymphoma
Anti-CD38 monoclonal antibodies (mAbs), daratumumab, and isatuximab have represented a breakthrough in the treatment of multiple myeloma (MM). Recently, CD38-based mAbs were expected to achieve increasing pote... (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - December 29, 2022 Category: Hematology Authors: Guangbing Zhang, Cuiyu Guo, Yan Wang, Xianda Zhang, Shuang Liu, Wen Qu, Chunxia Chen, Lingli Yan, Zhouning Yang, Zhixiong Zhang, Xiaohua Jiang, Xiaofeng Chen, Hong Liu, Qinhuai Lai, Xian Wei, Ying Lu & hellip; Tags: Correspondence Source Type: research
A novel tRNA-derived fragment tRF-3022b modulates cell apoptosis and M2 macrophage polarization via binding to cytokines in colorectal cancer
tRNA-derived fragments (tRFs) are a class of small RNAs that occur when tRNAs are broken down by enzymes due to stress. Increasing reports have shown that tRFs are associated with multiple physiological and pa... (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - December 16, 2022 Category: Hematology Authors: Sicheng Lu, Xiaoman Wei, Lihuiping Tao, Dan Dong, Wenlong Hu, Qinchang Zhang, Yuquan Tao, Chengtao Yu, Dongdong Sun and Haibo Cheng Tags: Correspondence Source Type: research
Correction: DACH1 antagonizes CXCL8 to repress tumorigenesis of lung adenocarcinoma and improve prognosis
(Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - December 13, 2022 Category: Hematology Authors: Qian Liu, Anping Li, Shengnan Yu, Shuang Qin, Na Han, Richard G. Pestell, Xinwei Han and Kongming Wu Tags: Correction Source Type: research
Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study
Brexucabtagene autoleucel (KTE-X19) is an autologous anti-CD19 CAR T-cell therapy approved in the USA to treat adult patients with relapsed or refractory B-precursor acute lymphoblastic leukemia (R/R B-ALL) ba... (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - December 10, 2022 Category: Hematology Authors: Bijal D. Shah, Armin Ghobadi, Olalekan O. Oluwole, Aaron C. Logan, Nicolas Boissel, Ryan D. Cassaday, Thibaut Leguay, Michael R. Bishop, Max S. Topp, Dimitrios Tzachanis, Kristen M. O ’Dwyer, Martha L. Arellano, Yi Lin, Maria R. Baer, Gary J. Schiller, Tags: Research Source Type: research
Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the preferential options for advanced non-small cell lung cancer (NSCLC) patients harboring EGFR mutations. Osimertinib is a potent i... (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - December 8, 2022 Category: Hematology Authors: Kai Fu, Fachao Xie, Fang Wang and Liwu Fu Tags: Review Source Type: research
Targeting cell death pathways for cancer therapy: recent developments in necroptosis, pyroptosis, ferroptosis, and cuproptosis research
Many types of human cells self-destruct to maintain biological homeostasis and defend the body against pathogenic substances. This process, called regulated cell death (RCD), is important for various biologica... (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - December 8, 2022 Category: Hematology Authors: Xuhui Tong, Rong Tang, Mingming Xiao, Jin Xu, Wei Wang, Bo Zhang, Jiang Liu, Xianjun Yu and Si Shi Tags: Review Source Type: research
Electrostatic anti-CD33-antibody –protamine nanocarriers as platform for a targeted treatment of acute myeloid leukemia
Acute myeloid leukemia (AML) is a fatal clonal hematopoietic malignancy, which results from the accumulation of several genetic aberrations in myeloid progenitor cells, with a worldwide 5-year survival prognos... (Source: Journal of Hematology and Oncology)
Source: Journal of Hematology and Oncology - December 1, 2022 Category: Hematology Authors: Nicole B äumer, Annika Scheller, Lisa Wittmann, Andreas Faust, Mara Apel, Subbaiah Chary Nimmagadda, Christiane Geyer, Katharina Grunert, Neele Kellmann, Matthias Peipp, Sareetha Kailayangiri, Matias Ezequiel Gutierrez Suburu, Cristian A. Strassert, Math Tags: Research Source Type: research
